KRAS and glioblastoma: In our experimental model, we did not force any oncogenic expression of active RAS, and RAS is not mutated in the glioblastoma cells used [18], in line with the low frequency of H-RAS, K-RAS and N-RAS mutations in glioblastoma patients [36, 37].